Advertisment

Nirsevimab: A Promising Monoclonal Antibody in Preventing Severe RSV Infections in Infants

author-image
Dr. Jessica Nelson
New Update
NULL

Nirsevimab: A Promising Monoclonal Antibody in Preventing Severe RSV Infections in Infants

Advertisment

A Groundbreaking Discovery in Infant Health

Advertisment

The health of infants is always a top priority, and recent developments in medical science have brought forth an exciting breakthrough. Nirsevimab, a monoclonal antibody targeting Respiratory Syncytial Virus (RSV), has been found to significantly decrease hospitalizations for RSV-associated lower respiratory tract infection in infants during their first RSV season. These results were observed in the HARMONIE trial, an open-label, pragmatic trial, and hold significant promise for the prevention of severe RSV infections in infants.

Nirsevimab: The Monoclonal Antibody for RSV

According to recent reports, the monoclonal antibody nirsevimab (Beyfortus) has the potential to reduce hospitalizations among infants with RSV-associated lower respiratory tract infection by a staggering 80%. Furthermore, it exhibited an efficacy rate of 83.2% in reducing hospitalizations for RSV-associated lower respiratory tract infection and 75.7% in very severe cases. The safety and effectiveness of nirsevimab have been confirmed, however, it is in short supply for the upcoming 2023-2024 RSV season in the U.S.

Advertisment

Impact of Nirsevimab on Hospital Admissions

The Harmonie study, which involved 8,000 children up to the age of 12 months in the UK, France, and Germany, offered some promising results. Half of the children received a single dose of the monoclonal antibody treatment nirsevimab. It was found that RSV-related hospitalization was reduced by 83% in those receiving the jab, and admissions for all chest infections were cut by 58%. Most of the side effects noticed were mild and similar in both groups.

Nirsevimab: Licensed and Rolled Out

Advertisment

Nirsevimab, which was produced by Sanofi, was licensed for use in the UK last year. The Joint Committee on Vaccination and Immunisation (JCVI) is currently considering whether to recommend the jab to protect infants. It is also reviewing data on an RSV vaccine given to pregnant women which was licensed last month. In the US, the Food and Drug Administration (FDA) approved nirsevimab for babies in July, and it has also been rolled out in parts of Spain.

Further Studies and Future Prospects

Further research involving 8,058 healthy babies from the UK, France, and Germany concluded that the vaccine nirsevimab could reduce the number of babies and young children admitted to hospital with RSV by 80%. The vaccine reduced the likelihood of hospital admission from six admissions per 1,000 to one admission per 1,000 in previously healthy infants. However, despite the approval for use in the UK, it is not yet offered within a vaccination programme.

Advertisment

Availability and Rollout of Nirsevimab

As the impact of nirsevimab becomes increasingly evident, efforts are underway to increase its availability. A plan is in motion to roll out 230,000 additional doses in January 2024. This will be a crucial step towards protecting more babies from the severe complications of RSV infection.

Expert Opinions and Considerations

Healthcare experts have voiced their opinions on the use of nirsevimab. Prof Peter Openshaw from Imperial College London described it as 'an exciting time for those of us working in the RSV field', highlighting the high efficacy and safety of nirsevimab. However, there are still questions about the cost-benefit analysis of implementing this treatment in the UK. Dr. Joe Brierley from Great Ormond Street Hospital emphasised that while the trial was very real-world and pragmatic, the cost to the NHS must also be considered.

Advertisment
Chat with Dr. Medriva !